References
[1] Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008 Sep;4(9):491-8. doi: 10.1038/ncprheum0895.
[2] Gilhus N, Skeie G, Romi F et al. Myasthenia gravis – autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12, 259-268(2016) https://doi.org/10.1038/nrneurol.2016.44.
[3] Bacci ED et al. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335. Doi:10.1186/s12883-019-1573-2 https://pubmed.ncbi.nlm.nih.gov/31864345/.
[4] Schett G, Teitelbaum SL. Osteoclasts and Arthritis. J Bone Miner Res. 2009;24(7):1142-1146. doi:10.1359/jbmr.090533.
[5] Kocijan R, Harre U, Schett G. ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep. 2013;15(10):366. doi:10.1007/s11926-013-0366-7.
[6] Sieghart D, Platzer A, Studenic P, et al. Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. Front Immunol. 2018;9:876. doi:10.3389/fimmu.2018.00876.
[7] Drug Target Review. Rare autoantibody diseases: on innovative targeted pathway. Available at: https://www.drugtargetreview.com/article/110647/rare-autoantibody-diseases-an-innovative-targeted-pathway.Last accessed: August 2025.
[8] Conrad N, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023 Jun 3;401(10391):1878-1890. doi: 10.1016/S0140-6736(23)00457-9.
[9] Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009 Nov-Dec;33(3-4):197-207. doi: 10.1016/j.jaut.2009.09.008. Epub 2009 Oct 9. PMID: 19819109; PMCID: PMC2783422.
[10] Law N, et al. The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis. Neurol Ther (2021). 10:1103–1125. Available at: https://doi.org/10.1007/s40120-021-00285-w.
[11] Bubuioc A, et al. The epidemiology of myasthenia gravis. Journal of Medicine & Life (2021). Jan-Mar;14(1):7-16. doi: 10.25122/jml-2020-0145.
[12] Dewilde S, et al. A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity. Frontiers in Public Health. 25 April 2025;13. Available at: https://doi.org/10.3389/fpubh.2025.1538789. Last accessed: August 2025.
[13] Myasthenia Gravis: Treatment & Symptoms. (2021, April 7). Retrieved June 18, 2025, from https://my.clevelandclinic.org/health/diseases/17252-myasthenia-gravis-mg.
[14] Myasthenia gravis fact sheet. Retrieved June 18, 2025, from https://www.ninds.nih.gov/sites/default/files/migrate-documents/myasthenia_gravis_e_march_2020_508c.pdf.
[15] Mahic, et al. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disorders (2023). Available at: https://doi.org/10.1177/17562864221150327 Last accessed: August 2025.
[16] Khateb M and Shelly S. Mortality risk in patients with myasthenia gravis. Front Neurol. 2025;16:1586031. doi: 10.3389/fneur.2025.1586031.
[17] Dewilde S, et al. People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies. Adv Ther. 2023;40:4377–4394. Available at: https://doi.org/10.1007/s12325-023-02604-z. Last accessed: August 2025.
[18] Sacca F, et al. Burden of remaining symptoms and fluctuations of generalized myasthenia gravis on patients’ daily lives – BEYOND study. Poster presented at EAN 2025 (21-24 June 2025). [A-25-14113].
[19] Sobierajsky T, et al. Diagnosis and therapy of myasthenia gravis – the patients’ perspective: a cross sectional study. Front. Neurol. 14:1214041. doi: 10.3389/fneur.2023.1214041.
[20] Borsi A, et al. Delayed diagnosis amongst Generalized Myasthenia Gravis patients: Results from a European real-world study. Poster presented at IPOR EU 2022 (6-9 November 2022).
[21] National Institute of Neurological Disorders and Stroke. Health information: myasthenia gravis. Available at: https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis. Last accessed: August 2025.
[22] Mahic M, et al. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey. Orphanet Journal of Rare Diseases (2023) 18:169. https://doi.org/10.1186/s13023-023-02727-0.
[23] World Health Organization. ATLAS country resources for neurological disorders (second edition). Available at: https://iris.who.int/bitstream/handle/10665/258947/9789241565509-eng.pdf?sequence=1. Last accessed: August 2025.
[24] Monsul NT, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. Journal of the Neurological Sciences. 2004; 217(2):131-133.
[25] NHS. Myasthenia gravis – treatment. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/treatment/. Last accessed: August 2025.
[26] Cortes-Vicente E, et al. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology 2022; 9(2):122–131. doi: 10.1002/acn3.51492.
[27] Gilhus, N.E., Tzartos, S., Evoli, A. et al. Myasthenia gravis. Nat Rev Dis Primers 5, 30 (2019). https://doi.org/10.1038/s41572-019-0079-y
[28] Kaminski HJ, Denk J. Corticosteroid Treatment-Resistance in Myasthenia Gravis. Front Neurol. 2022 Apr 25;13:886625. doi: 10.3389/fneur.2022.886625. PMID: 35547366; PMCID: PMC9083070.
[29] Dodd KC, et al. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis. Neuromuscular Disorders. 2024;34:51-57.
[30] Alhaidar MK, et al. Current Treatment of Myasthenia Gravis. J Clin Med. 2022;11(6):1597. doi: 10.3390/jcm11061597.
[31] European Commission. Towards a Strategy for European Life Sciences. Available at: https://research- and-innovation.ec.europa.eu/strategy/strategy-research-and-innovation/jobs-and-economy/towards-strategy-european-life-sciences_en. Last accessed: August 2025.
[32] European Parliamentary Research Service (EPRS). Briefing: New European biotech act. Which way forward? Available at: https://www.europarl.europa.eu/RegData/etudes/BRIE/2025/772866/EPRS_BRI(2025)772866_EN.pdf. Last accessed: August 2025.
CP-537712 | September 2025
